Safety and efficacy assessment of Synskin “ Acnes 2 cream” and “ Acnes 3 cream” for treatment of acne

Safety and efficacy assessment of “Synskin Acnes 2 acute phase cream” and “Synskin Acnes 3 chronic phase cream” for treatment of mild to moderate acne vulgaris

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190210042676N14

Enrollment

Registered

2021-06-11

Start date

2021-06-22

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris. Acne vulgaris

Interventions

Intervention group: Topical use of “Synskin Acnes 2 acute phase cream” (Contains anti-acne compounds such as Tea tree extract, Niacin amid, Vitamin A, etc..) for 2 weeks twice a day and then “Synskin

Eligibility

Sex/Gender

All

Age

16 Years to 40 Years

Inclusion criteria

Inclusion criteria: Male or female aged 16-40 years Mild to moderate inflammatory or non-inflammatory acne lesions (grade 1 to 3 according to the table) on face

Exclusion criteria

Exclusion criteria: People with allergies to formulation ingredients Nodular or cystic lesions that represent a severe type of acne vulgaris

Design outcomes

Primary

Measure	Time frame
Evaluate the improvement of acne severity index by a physician. Timepoint: Before intervention, 2, 6 and 10 weeks after the start of use. Method of measurement: 0=normal skin, 2=skin is almost clear, 3=some non-inflammatory lesions are present, 4=non-inflammatory lesions are predominant, with multiple inflammatory lesions. 5=highly inflammatory lesions predominate.	—

Secondary

Measure	Time frame
Trans Epidermal Water Loss. Timepoint: Before intervention, 2, 6 and 10 weeks after the start of use. Method of measurement: Tewameter.;Skin sebum. Timepoint: Before intervention, 2, 6 and 10 weeks after the start of use. Method of measurement: Sebumeter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026